{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T16:34:28Z","timestamp":1793637268568,"version":"4.5.1"},"reference-count":31,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2010,6,8]],"date-time":"2010-06-08T00:00:00Z","timestamp":1275955200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[2010,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the efficacy and tolerability of canakinumab, a fully human anti\u2013interleukin\u20101\u03b2 monoclonal antibody, for the treatment of acute gouty arthritis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this 8\u2010week, single\u2010blind, double\u2010dummy, dose\u2010ranging study, patients with acute gouty arthritis whose disease was refractory to or who had contraindications to nonsteroidal antiinflammatory drugs and\/or colchicine were randomized to receive a single subcutaneous dose of canakinumab (10, 25, 50, 90, or 150 mg; n = 143) or an intramuscular dose of triamcinolone acetonide (40 mg; n = 57). Patients assessed pain using a 100\u2010mm visual analog scale.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Seventy\u2010two hours after treatment, a statistically significant dose response was observed for canakinumab. All canakinumab doses were associated with numerically less pain than triamcinolone acetonide; thus, a dose with equivalent efficacy to triamcinolone acetonide 72 hours after treatment could not be determined. The reduction from baseline in pain intensity with canakinumab 150 mg was greater than with triamcinolone acetonide 24, 48, and 72 hours after treatment (differences of \u221211.5 mm [\n                      <jats:italic>P<\/jats:italic>\n                      = 0.04], \u221218.2 mm [\n                      <jats:italic>P<\/jats:italic>\n                      = 0.002], and \u221219.2 mm [\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001], respectively), and 4, 5, and 7 days after treatment (all\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.05). Canakinumab significantly reduced the risk of recurrent flares versus triamcinolone acetonide (\n                      <jats:italic>P<\/jats:italic>\n                      \u2264 0.01 for all doses) (relative risk reduction 94% for canakinumab 150 mg versus triamcinolone acetonide). The overall incidence of adverse events was similar for canakinumab (41%) and triamcinolone acetonide (42%); most were mild or moderate in severity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings indicate that canakinumab 150 mg provides rapid and sustained pain relief in patients with acute gouty arthritis, and significantly reduces the risk of recurrent flares compared with triamcinolone acetonide.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/art.27600","type":"journal-article","created":{"date-parts":[[2010,6,8]],"date-time":"2010-06-08T14:53:21Z","timestamp":1276008801000},"page":"3064-3076","source":"Crossref","is-referenced-by-count":264,"title":["Canakinumab for the treatment of acute flares in difficult\u2010to\u2010treat gouty arthritis: Results of a multicenter, phase II, dose\u2010ranging study"],"prefix":"10.1002","volume":"62","author":[{"given":"Alexander","family":"So","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"De Meulemeester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey","family":"Pikhlak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Eftal","family":"Y\u00fccel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valda","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udayasankar","family":"Arulmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Sallstig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Schlesinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,6,8]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar2509"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.2002.33911"},{"key":"e_1_2_7_4_2","first-page":"S443","article-title":"Diagnosis of gout: clinical, laboratory, and radiologic findings","volume":"11","author":"Schlesinger N","year":"2005","journal-title":"Am J Manag Care"},{"key":"e_1_2_7_5_2","first-page":"759","article-title":"Diagnosis of gout","volume":"98","author":"Schlesinger N","year":"2007","journal-title":"Minerva Med"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200464210-00003"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.055269"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200868040-00002"},{"key":"e_1_2_7_9_2","first-page":"1566","article-title":"Treatment of acute gout in hospitalized patients","volume":"34","author":"Petersel D","year":"2007","journal-title":"J Rheumatol"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006190"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature04516"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncprheum0681"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810787"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055137"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.23687"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar2143"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.23119"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2009.01.001"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.108936"},{"issue":"3","key":"e_1_2_7_20_2","first-page":"680","article-title":"Placebo\u2010controlled study of rilonacept for prevention of gout flares during initiation of urate\u2010lowering therapy","volume":"68","author":"Schumacher RH","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar2438"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20082481"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780200320"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1541-0420.2005.00344.x"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.081604"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050373"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.4065\/81.7.925"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.28.4.437"},{"key":"e_1_2_7_29_2","first-page":"111","article-title":"Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis","volume":"20","author":"Alloway JA","year":"1993","journal-title":"J Rheumatol"},{"key":"e_1_2_7_30_2","first-page":"1325","article-title":"Comparison of adrenocorticotropic hormone and triamcinolone acetonide in the treatment of acute gouty arthritis","volume":"21","author":"Siegel LB","year":"1994","journal-title":"J Rheumatol"},{"key":"e_1_2_7_31_2","first-page":"1582","article-title":"Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population","volume":"31","author":"Wallace KL","year":"2004","journal-title":"J Rheumatol"},{"key":"e_1_2_7_32_2","first-page":"CD005521","article-title":"Systemic corticosteroids for acute gout","author":"Janssens HJ","year":"2008","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Arthritis &amp; Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.27600","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.27600","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T21:15:59Z","timestamp":1698700559000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.27600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,8]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["10.1002\/art.27600"],"URL":"https:\/\/doi.org\/10.1002\/art.27600","archive":["Portico"],"relation":{},"ISSN":["0004-3591","1529-0131"],"issn-type":[{"value":"0004-3591","type":"print"},{"value":"1529-0131","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,8]]}}}